After receiving recent FDA feedback regarding supplemental assay validation information and comparability data for lifileucel (LN-44) in the treatment of advanced melanoma, Iovance Biotherapeutics will address these comments and plans to complete its rolling biologics license application (BLA) submission during the first quarter of 2023.
2022
Microsatellites may be associated with poorer survival outcomes in melanoma
Varying therapies for the neoadjuvant and adjuvant treatment of melanoma based on staging continue to be explored with pembrolizumab (Keytruda) a common agent in both settings, according to Sapna Patel, MD.
Bendigo Health unveils new machine with 3D imaging to help diagnose melanoma quicker
After receiving recent FDA feedback regarding supplemental assay validation information and comparability data for lifileucel (LN-44) in the treatment of advanced melanoma, Iovance Biotherapeutics will address these comments and plans to complete its rolling biologics license application (BLA) submission during the first quarter of 2023.
Revised Classification Criteria Needed Due to Melanoma Overdiagnosis
Increasing rates of melanoma diagnosis in recent years may be due to overdiagnosis of the skin cancer in patients with a very low risk of death and stage 1 lesions that are 1 mm or smaller, according to recent study findings in Cancer.